Stockreport

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara, Inc.  (SVRA) 
Last savara, inc. earnings: 3/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: savarapharma.com/investors/events-presentations
PDF -- Day 74 Letter Received from the U.S. Food and Drug Administration (FDA) Indicated the Agency Has No Plans to Convene an Advisory Committee ---- Company has Submitted [Read more]